TVRD
Tvardi TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Composite grade F from latest DB weights. Momentum 7.1 / Value 58.3
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
7
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.67
Why
Momentum7 · Δ7d -
Value58 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
7
52% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
48% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+17.3
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 7.1 / Value 58.3
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$29.74M
Beta
0.14
Shares Out
9.38M
P/E (TTM) · Derived
-0.1
P/S (TTM)
9.40
P/FCF (TTM) · Derived
-0.25
Rev YoY
-100.0%
EPS YoY
+72.5%
Gross Margin
+100.0%
Op Margin
-573.3%
Net Debt
-$37.9M
Current Ratio
3.48
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology